Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Hsiehchen

Showing results (41-50 of 63) with videos related to

Pageof 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2023
Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04)Arathi Mohan, Kent A Griffith, Fulei Wuchu, et al.
Frontiers in Immunology|May 1, 2024
Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practiceMitchell S von Itzstein, Yuqiu Yang, Yiqing Wang, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 30, 2025
Racial and Ethnic Disparities in Survival Among Patients with Cholangiocarcinoma in the United States: A Systematic Review and Meta-AnalysisAndrew D Shubin, Phillip J Leff, Meena M Tadros, et al.
Journal for Immunotherapy of Cancer|June 15, 2021
Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitorsMurtaza Ahmed, Mitchell S von Itzstein, Thomas Sheffield, et al.
Clinical Colorectal Cancer|October 25, 2022
Trends in Adjuvant Chemotherapy Use Among Stage III Colon Cancer in Non-Elderly and Low Comorbidity PatientsJoanna El Hajj, Mohsin Soleja, Suleyman Y Goksu, et al.
Cell Metabolism|June 20, 2024
PKD1 mutant clones within cirrhotic livers inhibit steatohepatitis without promoting cancerMin Zhu, Yunguan Wang, Tianshi Lu, et al.
JCO Oncology Practice|January 11, 2021
Disparities in Characteristics, Access to Care, and Oncologic Outcomes in Young-Onset Colorectal Cancer at a Safety-Net HospitalBenjamin D Fangman, Suleyman Y Goksu, Nivan Chowattukunnel, et al.
Cancer Cell|November 22, 2024
Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activationDavid Hsiehchen, Andrew Elliott, Joanne Xiu, et al.
Nature Cancer|March 26, 2024
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancersMaishara Muquith, Magdalena Espinoza, Andrew Elliott, et al.
Cancers|March 10, 2022
Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint Inhibitor TherapyMitchell S von Itzstein, Amrit S Gonugunta, Thomas Sheffield, et al.
Pageof 7

Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2023
Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04)Arathi Mohan, Kent A Griffith, Fulei Wuchu, et al.
Frontiers in Immunology|May 1, 2024
Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practiceMitchell S von Itzstein, Yuqiu Yang, Yiqing Wang, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 30, 2025
Racial and Ethnic Disparities in Survival Among Patients with Cholangiocarcinoma in the United States: A Systematic Review and Meta-AnalysisAndrew D Shubin, Phillip J Leff, Meena M Tadros, et al.
Journal for Immunotherapy of Cancer|June 15, 2021
Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitorsMurtaza Ahmed, Mitchell S von Itzstein, Thomas Sheffield, et al.
Clinical Colorectal Cancer|October 25, 2022
Trends in Adjuvant Chemotherapy Use Among Stage III Colon Cancer in Non-Elderly and Low Comorbidity PatientsJoanna El Hajj, Mohsin Soleja, Suleyman Y Goksu, et al.
Cell Metabolism|June 20, 2024
PKD1 mutant clones within cirrhotic livers inhibit steatohepatitis without promoting cancerMin Zhu, Yunguan Wang, Tianshi Lu, et al.
JCO Oncology Practice|January 11, 2021
Disparities in Characteristics, Access to Care, and Oncologic Outcomes in Young-Onset Colorectal Cancer at a Safety-Net HospitalBenjamin D Fangman, Suleyman Y Goksu, Nivan Chowattukunnel, et al.
Cancer Cell|November 22, 2024
Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activationDavid Hsiehchen, Andrew Elliott, Joanne Xiu, et al.
Nature Cancer|March 26, 2024
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancersMaishara Muquith, Magdalena Espinoza, Andrew Elliott, et al.
Cancers|March 10, 2022
Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint Inhibitor TherapyMitchell S von Itzstein, Amrit S Gonugunta, Thomas Sheffield, et al.
Pageof 7